|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400083271 |
|
最近更新日期: Date of Last Refreshed on: |
2024-04-19 14:27:49 |
|
注册时间: Date of Registration: |
2024-04-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中药随机对照试验偏倚风险评估体系(cRoB)评价研究 |
|
Public title: |
Evaluation of risk of bias tool for randomized controlled trials of traditional Chinese medicine (cRoB) |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中药随机对照试验偏倚风险评估体系(cRoB)评价研究 |
|
Scientific title: |
Evaluation of risk of bias tool for randomized controlled trials of traditional Chinese medicine (cRoB) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
向玲慧 |
研究负责人: |
向玲慧 |
|
Applicant: |
Xiang Linghui |
Study leader: |
Xiang Linghui |
|
申请注册联系人电话: Applicant telephone: |
+86 185 7014 4366 |
研究负责人电话:
Study leader's |
+86 185 7014 4366 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
Xiang.Linghui@outlook.com |
研究负责人电子邮件: Study leader's E-mail: |
Xiang.Linghui@outlook.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市湘雅路110号 |
研究负责人通讯地址: |
湖南省长沙市湘雅路110号 |
|
Applicant address: |
110 XiangYa Road, Changsha, Hunan, China |
Study leader's address: |
110 XiangYa Road, Changsha, Hunan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅公共卫生学院 |
||
|
Applicant's institution: |
Xiangya School of Public Health, Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅公共卫生学院 |
||
|
Affiliation of the Leader: |
Xiangya School of Public Health, Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XYGW-2024-47号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅公共卫生学院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee, Xiangya School of Public Health, Central South University, China |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-03-28 00:00:00 | ||
|
伦理委员会联系人: |
关岚 |
||
|
Contact Name of the ethic committee: |
Guan Lan |
||
|
伦理委员会联系地址: |
湖南省长沙市湘雅路110号 |
||
|
Contact Address of the ethic committee: |
110 XiangYa Road, Changsha, Hunan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 133 9745 3611 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中南大学湘雅公共卫生学院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiangya School of Public Health, Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市湘雅路110号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
110 XiangYa Road, Changsha, Hunan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金面上项目(No. 81973709) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (No. 81973709) |
||||||||||||||||||||||
|
研究疾病: |
偏倚风险评估工具 |
||||||||||||||||||||||
|
Target disease: |
Risk of bias tool |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
开展随机对照试验研究,以评价和比较cRoB与考克兰偏倚风险评估工具2(RoB2)的信度以及偏倚风险评估结果差异 |
||||||||||||||||||||||
|
Objectives of Study: |
Conduct a randomized controlled trial study to evaluate and compare the reliability of cRoB versus RoB2 and differences in risk of bias assessment results |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)湖南省长沙市内医学院特定专业(包含临床医学、护理学、公共卫生与预防医学、中医学、中西医结合和中药学)的在读博士、硕士研究生(2)没有以(共同)第一作者/通讯作者身份发表过有关RCT的meta分析(3)未接受过偏倚风险评价训练(4)同意参加本研究者。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Doctoral and master's degree students enrolled in specific specialties (including clinical medicine, public health and preventive medicine, traditional Chinese medicine, integrated Chinese and Western medicine, and traditional Chinese medicine) in medical schools within Changsha, Hunan Province (2) have not published meta-analyses of RCTs as (co-)first/corresponding authors (3) have not received training in the evaluation of the risk of bias (4) who agreed to participate in this study. |
||||||||||||||||||||||
|
排除标准: |
1.拒绝参与研究 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Refuse to participate in the research |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-04-20 00:00:00至 To 2024-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-20 00:00:00 至 To 2024-04-22 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参与后续研究的统计学专家进行最小化随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Minimized randomization by statisticians not involved in the follow-up study |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
仅对数据分析者实施盲法 |
|
Blinding: |
Blind method only for data analysts |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
N/A |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
N/A |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
N/A |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
N/A |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |